Diabetes Glucose Monitors Recalled After 7 Deaths and More Than 700 Injuries

Diabetes Glucose Monitor Recall Linked to Deaths and Injuries

Abbott Diabetes Care has issued a recall and urged patients to discontinue the use of certain glucose monitors following seven reported deaths and over 700 injuries associated with the devices.

The affected products, specifically the FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitors, were found to have malfunctioning sensors during internal testing, prompting Abbott to take action to prevent further harm to users.

The U.S. Food and Drug Administration (FDA) released a warning on December 2, revealing that Abbott’s internal testing uncovered issues with some sensors in the FreeStyle Libre 3 devices, potentially leading to inaccurate low glucose readings and a significant number of adverse events.

Abbott Diabetes Care stated in a press release that they have notified customers about the recall and provided necessary support. They have urged users to discontinue using the affected devices immediately. Patients impacted by the recall are advised to utilise a blood glucose meter or the built-in meter on a FreeStyle Libre 3 Reader for making treatment decisions in cases where sensor readings do not align with symptoms or expectations.

According to Abbott, the company has received reports of 736 severe adverse events, with 57 cases in the U.S., and sadly, seven deaths have been reported, all of which occurred outside the U.S. The FDA has classified this issue as “potentially high-risk.”

The company has identified the model numbers and unique device identifiers for the affected FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors, enabling users to check whether their devices are part of the recall. Abbott is offering replacements for the impacted sensors at no cost to the users. Users can visit www.FreeStyleCheck.com for further information on determining if their sensors are affected.

Blood glucose meters are crucial for individuals with diabetes to monitor their blood sugar levels accurately. Treatment decisions, diet adjustments, and medication dosages are often based on these readings, making the reliability of glucose monitors paramount for patient safety.

Abbott has assured the public that they have rectified the sensor issues and are actively producing unaffected Libre 3 and Libre 3 Plus sensors to meet replacement and new orders. They have also emphasised a continual supply chain to avoid significant disruptions in product availability.

It is essential for individuals who use glucose monitors to prioritise their health and safety by promptly checking if their devices are part of the recall. Ensuring the accuracy and reliability of medical devices is crucial in managing chronic conditions like diabetes and preventing potential severe health risks associated with incorrect readings.

In conclusion, patients are advised to heed the recall notice, discontinue the use of affected glucose monitors, and seek replacement sensors promptly to safeguard their well-being and prevent any potential health complications.